ReviewThe MAK collection for occupational health and safety2025
Tetrabromobisphenol A: MAK Value Documentation - Translation of the German version from 2023.
Review in The MAK collection for occupational health and safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The German Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (MAK Commission) has evaluated the data for tetrabromobisphenol A [79-94-7] considering all toxicological end points. Relevant studies were identified from a literature search, epidemiological studies of tetrabromobisphenol A are not available. After repeated administration by gavage, the target organs of toxicity were the endocrine system in male and female rats with decreased total T4 concentrations and the kidneys in male mice with cytoplasmic changes in the tubules. Tetrabromobisphenol A induces uterine tumours in female Wistar-Han rats and hepatoblastomas and haemangiosarcomas in male B6C3F1/N mice. Due to its non-genotoxic mechanism of action, it is assumed that a NAEL (no adverse effect level) can be determined for carcinogenic effects. Therefore, tetrabromobisphenol A could be classified in Carcinogen Category 4. However, there are no data that can be used to establish a NOAEL for atypical hyperplasia (preneoplasia) in the endometrium, to clarify whether the observed uterine tumours are specific to the strain, and to further characterize the mechanism of tumourigenesis. Therefore, a maximum concentration at the workplace (MAK value) cannot be established and tetrabromobisphenol A has been classified in Carcinogen Category 2 and given the footnote "Prerequisite for Category 4 in principle fulfilled, but insufficient data available for the establishment of a MAK or BAT value". Tetrabromobisphenol A is not mutagenic in bacteria or clastogenic in mammalian cells. In vivo data do not provide evidence of genotoxic effects in soma cells, even at concentrations that cause systemic toxicity. In vivo studies suggest that transdermal uptake may be relevant. As tetrabromobisphenol A has been classified as a Category 2 carcinogen and no threshold for the carcinogenic effects can be established at present, the substance has provisionally been designated with "H". Data for humans, animals and from in vitro studies show no sensitizing potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.